证券研究报告 2026 年 01 月 04 日 湘财证券研究所 行业研究 中药行业周报 中药饮片纳入全国统一药品追溯码体系正在加快推进 相关研究： 核心要点： ❑ 市场表现：上周中药Ⅱ下跌 1.67%，跌幅相对较小 根据 wind 数据，上周（2025.12.28-2026.01.03）医药生物报收 8084.61 点，下跌 2.06%；中药Ⅱ报收 6234.32 点，下跌 1.67%；化学制药报收 12742.31 点，下跌 2.34%；生物制品报收 6071.66 点，下跌 1.86%；医药商业报收 5280.19 点，下跌 2.68%；医疗器械报收 6302.86 点，下跌 2.33%；医疗服务报收 6273.96 点，下跌 1.4%。医药板块整体回调，中药板块跌幅相对较小。 从公司表现来看，根据 wind 数据，表现居前的公司有：万邦德、天目药业、 古汉医药、沃华医药、康惠股份；表现靠后的公司有：*ST 长药、ST 葫芦娃、 珍宝岛、众生药业、ST 百灵。 ❑ 估值：上周中药板块 PE（ttm）为 26.63X，PB（lf）为 2.24X 近期国家医保局发布《中药饮片追溯码编码规则》公开征求意见，《中 ...

为推动平台经济创新和健康发展，国家发展改革委、市场监管总局、国家网信办近日发布《互联网平台 价格行为规则》（以下简称《行为规则》），健全互联网平台常态化价格监管机制，规范相关价格行 为，保护消费者和经营者合法权益。 推动构建良好平台生态 国家发展改革委有关负责人介绍，国家发展改革委、市场监管总局、国家网信办于今年8月23日至9月22 日就《行为规则》公开征求社会意见。根据各方意见，有关部门进一步修改完善了《行为规则》，着力 规范价格行为、推动公开透明、增强各方协同，构建良好平台生态。 一是规范价格竞争秩序。根据现行法律法规规定，细化实化监管要求，为平台经营者、平台内经营者提 供明确的价格行为指引，推动形成优质优价、良性竞争的市场秩序。二是保护经营者自主定价权。完善 对平台内经营者自主定价权的保护规定，明确平台经营者不得对平台内经营者的价格行为进行不合理限 制或者附加不合理条件。三是保护消费者合法权益。落实明码标价制度，推动动态定价、差别定价等规 则公开，规范免密支付、自动续期、自动扣款等服务。 国家发展改革委宏观经济研究院研究员张林山在接受本报记者采访时表示，《行为规则》的出台，是中 国平台经济价格治理迈向制 ...

Macro Strategy - In October, industrial enterprise profits showed a significant decline, with a year-on-year drop from 21.60% in September to -5.5% in October, leading to a cumulative year-on-year growth rate decrease from 3.20% to 1.90% [2] - The A-share market experienced a rebound from November 24 to November 28, with major indices such as the Shanghai Composite Index rising by 1.40% and the ChiNext Index increasing by 4.54% [3][4] - The rebound in A-shares was attributed to a reversal in the market's previous downward momentum, driven by a shift in expectations regarding the Federal Reserve's interest rate decisions and a recovery in the technology sector [3][4] Industry and Company Analysis Traditional Chinese Medicine Industry - The Traditional Chinese Medicine (TCM) sector saw a slight increase of 1.29% last week, the smallest among secondary sub-sectors in the pharmaceutical industry [9] - The price index for TCM materials showed a slight increase of 0.4%, indicating a recovery in market conditions and improved investor sentiment [12] - Multiple regions have initiated price governance for traditional Chinese medicine, aiming to create a unified and competitive market structure [13] Investment Recommendations - The report maintains an "overweight" rating for the TCM industry, suggesting three main investment themes: 1. Price governance, focusing on companies with strong R&D capabilities and unique products that can benefit from price reductions [15] 2. Consumption recovery, driven by macroeconomic improvement and increased health awareness among the aging population, favoring leading TCM brands [16] 3. State-owned enterprise reform, which is expected to enhance performance and create investment opportunities [16] - Recommended stocks include Zhaoli Pharmaceutical and Yiling Pharmaceutical, with a focus on companies with strong R&D capabilities and unique products [16]

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the sector [5]. Core Insights - The demand for respiratory medications is expected to rise due to the increase in flu cases, with a reported 955 flu-like illness outbreaks, marking a 53.8% increase from the previous week [4]. - The market performance of the Traditional Chinese Medicine (TCM) sector showed a decline of 6.46% last week, ranking second among secondary pharmaceutical sectors [1]. - The TCM sector's Price-to-Earnings (PE) ratio (ttm) is 27.36X, down by 1.89X week-on-week, while the Price-to-Book (PB) ratio (lf) is 2.31X, down by 0.16X [2]. Market Performance - The TCM sector reported a closing index of 6419.16 points, down 6.46% for the week, while the overall pharmaceutical sector index fell by 6.88% [1][16]. - Among companies, *ST Changyao, Weikang Pharmaceutical, Jiangzhong Pharmaceutical, Yunnan Baiyao, and Dong'e Ejiao showed better performance, while Te Yi Pharmaceutical, Panlong Pharmaceutical, Zhendong Pharmaceutical, Yiling Pharmaceutical, and Enwei Pharmaceutical lagged [1]. Valuation Metrics - The TCM sector's PE ratio is at the 28.94% percentile since 2013, while the PB ratio is at the 5.93% percentile, indicating relatively low valuation compared to historical data [2]. Supply Chain Insights - The market for TCM raw materials is currently weak, with a price index of 224.73 points, reflecting a 0.3% decrease due to oversupply and inventory buildup [3]. Investment Recommendations - Three main investment themes are highlighted: 1. Price governance focusing on competitive advantages and innovation capabilities [5]. 2. Consumption recovery driven by macroeconomic improvement and aging population [5]. 3. State-owned enterprise reform, which is expected to enhance efficiency and performance [5]. Target Companies - Recommended companies include Zhaoli Pharmaceutical and Yiling Pharmaceutical, with a focus on those with strong R&D capabilities and unique products [9].

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the traditional Chinese medicine sector [6]. Core Insights - The traditional Chinese medicine sector showed resilience with a 0.81% increase in the index, while the broader pharmaceutical sector declined by 2.4% [2]. - The price-to-earnings (PE) ratio for the traditional Chinese medicine sector is 28.11X, reflecting a slight increase, while the price-to-book (PB) ratio stands at 2.37X, also showing a minor rise [3]. - The recent price index for traditional Chinese medicinal materials has increased by 0.2%, indicating a slight upward trend in the market [4]. - The fourth batch of national procurement for traditional Chinese medicine has been announced, including 90 varieties, which presents both challenges and opportunities for production companies [5]. Summary by Sections Market Performance - The traditional Chinese medicine index closed at 6593.95 points, with a weekly increase of 0.81%, contrasting with declines in other pharmaceutical sectors [2][11]. - Notable performers in the sector include ST HuLuWa, DaRenTang, and ZhongSheng Pharmaceutical, while companies like WanBangDe and QiDi Pharmaceutical lagged [2]. Valuation - The PE ratio for the traditional Chinese medicine sector is currently at 28.11X, with a year-to-date maximum of 30.26X and a minimum of 24.72X [3]. - The PB ratio is at 2.37X, with a maximum of 2.59X and a minimum of 2.17X over the past year [3]. Raw Material Prices - The price index for traditional Chinese medicinal materials has shown a slight increase, with 9 categories rising and 3 falling in the past week [4]. Focus on National Procurement - The fourth batch of national procurement includes 90 varieties, with a focus on products that have significant demand and established clinical applications [5]. Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [6][9]. - Specific recommendations include companies with strong R&D capabilities, those less affected by procurement impacts, and leading brand enterprises in traditional Chinese medicine [9].

Group 1: PPI and Asset Prices - The PPI has stabilized, with a month-on-month change of 0 for the second consecutive month, indicating a potential trend in domestic asset prices[1] - Despite the current international oil price affecting related industries, there is a strong expectation for future easing by the Federal Reserve, supporting prices of commodities like gold and copper[1] - The implementation of anti-involution policies is showing results in key sectors like photovoltaics and new energy, with significant price increases observed post-National Day[1] Group 2: Market Performance - From October 11 to October 18, the CSI 300 index fell by 2.23%, while the Hang Seng Index dropped by 3.97%, and the S&P 500 rose by 1.71%[2] - The 10-year China bond yield increased by 0.41 basis points, while the 10-year US Treasury yield decreased by 3.01 basis points[2] - The US dollar index decreased by 0.27%, and the offshore RMB appreciated by 0.3%[2] Group 3: Inventory and Fund Behavior - The latest oil inventory stands at 44,355 million tons, up by 2.78 million tons from the previous week[3] - The latest week saw a rise in gold ETF holdings to 3,366 million ounces, an increase of 960,000 ounces[3] - The dollar long position increased by 1,541 contracts to 14,032, while the short position decreased by 1,009 contracts to 24,376[3] Group 4: Economic Indicators - Fixed asset investment year-on-year change is at -0.50%[5] - Retail sales year-on-year growth is at 3.00%[5] - Exports year-on-year growth is at 8.30%[5] - M2 growth rate is at 8.40%[5]

Investment Rating - The industry maintains an "Overweight" rating [8] Core Insights - The Chinese medicine sector outperformed other pharmaceutical sub-sectors last week, with a 0.38% increase, while the overall pharmaceutical sector declined by 2.48% [2] - The current PE (ttm) for the Chinese medicine sector is 27.9X, which is at the 30.45% percentile since 2013, while the PB (lf) is 2.36X, at the 6.85% percentile since 2013 [3] - The price index for Chinese medicinal materials remained stable due to the National Day holiday, with a total index of 232.77 points [4] - A pilot program for disease-based payment for traditional Chinese medicine (TCM) is set to begin, which may enhance reimbursement for TCM services [5] Summary by Sections Market Performance - The Chinese medicine sector recorded a 0.38% increase, while the overall pharmaceutical sector saw a decline of 2.48% [2] - Top-performing companies in the sector include Guizhou BaiLing, Wanbangde, and Darentang, while underperformers include Tianmu Pharmaceutical and Tailong Pharmaceutical [2] Valuation - The PE (ttm) for the Chinese medicine sector is 27.9X, up 0.1X week-on-week, with a one-year maximum of 30.26X and a minimum of 24.72X [3] - The PB (lf) is 2.36X, unchanged from the previous week, with a one-year maximum of 2.59X and a minimum of 2.17X [3] Policy Developments - The pilot program for TCM payment will select around 15 provinces or cities to test the new payment model over 2-3 years, potentially improving the compatibility of TCM services with existing insurance payment methods [5] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [6][11][12] - Specific recommendations include companies with strong R&D capabilities and unique products, as well as those less affected by price reductions from centralized procurement [12]

Core Viewpoint - The 2025 Golden Week saw a significant increase in domestic travel and spending, indicating a stable growth in total consumption, but further efforts are needed to stimulate consumer confidence and market order [2][3]. Group 1: Economic Performance - During the 8-day holiday, there were 888 million domestic trips, an increase of 123 million compared to the 2024 National Day holiday [2]. - Total domestic spending reached 809 billion yuan, up by 108.19 billion yuan from the previous year [2]. Group 2: Market Regulation - The National Development and Reform Commission and the State Administration for Market Regulation issued an announcement to combat price disorder and maintain a fair market price order [2][3]. - The announcement includes a three-step approach: industry average cost investigation, warning reminders, and law enforcement inspections to address issues like below-cost pricing [2]. Group 3: Demand Management - Price governance is seen as a starting point for demand expansion, emphasizing the need for both short-term stimulus and long-term structural reforms [4]. - Short-term measures should focus on fiscal expansion and monetary policy coordination to meet economic development goals [4]. Group 4: Long-term Strategies - Strategies to stimulate domestic demand should include promoting consumption upgrades and addressing livelihood shortcomings to support the next growth cycle [4][5]. - Emphasis on income distribution reform is crucial to enhance consumer spending power and address insufficient domestic demand [5].

Core Viewpoint - The market is experiencing fluctuations, with strong interest in relatively stable performance and high valuation products, particularly in the traditional Chinese medicine (TCM) sector, as evidenced by the recent performance of the Chinese Medicine ETF (560080) [1][2]. Market Performance - The Chinese Medicine ETF (560080) closed down 0.54% with a trading volume of nearly 100 million yuan, while maintaining a premium rate of 0.24% at the close [1]. - The ETF has seen a net inflow of over 178 million yuan over the past 10 days, reaching a record high in fund shares since its listing [1][2]. - The financing balance for the Chinese Medicine ETF has exceeded 70 million yuan, indicating strong investor interest [1]. Valuation Metrics - The dynamic price-to-earnings (P/E) ratio of the TCM sector is at a low since 2021, with the CSI Traditional Chinese Medicine Index TTM P/E ratio at 25.76x as of September 12, 2025 [3]. Stock Performance - Most major components of the Chinese Medicine ETF saw declines, with notable drops including Da Ren Tang down over 2% and Dong E E Jiao down over 1% [5]. - Conversely, Zhongheng Group increased nearly 4%, while Yunnan Baiyao and Zhongsheng Pharmaceutical saw slight increases [5]. Policy Developments - A recent government plan aims to accelerate the promotion of TCM at the grassroots level, with a goal for every county-level TCM hospital to establish at least two specialty departments and one TCM technology promotion center by 2030 [7]. - The National Health Commission is working on revising the National Essential Medicines List, which could further promote the application of TCM in grassroots markets [7]. Investment Opportunities - Three main investment themes in the TCM sector are identified: 1. Price governance, focusing on competitive advantages and the ability to exchange price for volume [8]. 2. Consumption recovery driven by macroeconomic improvement and aging population trends [8]. 3. State-owned enterprise reform, which is expected to enhance performance and create investment opportunities [9]. Recommendations - Investors are advised to focus on companies with strong R&D capabilities, those less affected by centralized procurement, and those with strong brand power and product offerings [9].

Investment Rating - The industry rating is maintained at "Overweight" [7] Core Views - The market performance of the traditional Chinese medicine (TCM) sector showed a slight increase of 0.03% last week, while the overall pharmaceutical sector experienced a minor decline of 0.36% [2] - The TCM sector's PE (ttm) is at 28.52X, with a PB (lf) of 2.42X, indicating a stable valuation compared to historical data [3] - The demand for TCM materials is expected to rise as the traditional medication peak season approaches, leading to a rebound in market conditions [4] - The promotion of TCM at the grassroots level is anticipated to accelerate, supported by government initiatives to enhance TCM services in community health centers and county hospitals [5][6] Market Performance - The TCM sector's index closed at 6720.55 points, reflecting a 0.03% increase, while the pharmaceutical sector index was at 9157.77 points, down 0.36% [2][18] - The performance of individual companies within the TCM sector varied, with leading companies including Yiling Pharmaceutical and Wanbangde, while companies like Kangyuan Pharmaceutical and Zhendong Pharmaceutical lagged [2][15][17] Valuation - The TCM sector's PE (ttm) is at 28.52X, unchanged from the previous week, with a one-year maximum of 30.26X and a minimum of 22.58X [3] - The PB (lf) stands at 2.42X, also stable, with a one-year maximum of 2.65X and a minimum of 1.99X [3] Policy and Regulatory Environment - The State Council's recent approval of the "Healthcare Strengthening Foundation Project" aims to enhance the use of TCM in grassroots healthcare settings, which is expected to significantly impact the sector [5] - The National Health Commission's response regarding the basic drug directory management indicates potential adjustments that could favor TCM applications in grassroots markets [6] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [10][11] - Specific investment targets include companies with strong R&D capabilities, those less affected by centralized procurement, and leading TCM brands [10][11]